SCHEMBL3147602

SCHEMBL3147602

CC(C)Cc1ccc([C@@H](C)C(=O)Nc2cnccn2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.66
MAPK1 P28482 1/20 0.66
LMNA P02545 1/20 0.59
XBP1 P17861 1/20 0.59
FAAH O00519 1/20 0.59
CHRM1 P11229 1/20 0.56
PDE4A P27815 1/20 0.56
CXCR1 P25024 3/20 0.56
CXCR2 P25025 3/20 0.56
MAPT P10636 2/20 0.55
CRHBP P24387 2/20 0.55
CRHR2 Q13324 2/20 0.55
GAA P10253 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
FFAR2 O15552 1/20 0.54
NPSR1 Q6W5P4 1/20 0.53
THRB P10828 1/20 0.52
EPHX1 P07099 1/20 0.51
NPC1 O15118 1/20 0.51
CA12 O43570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3151218 0.83 MAPK1 (0.76) RAB9AMAPK1LMNAXBP1FAAH
SCHEMBL3155546 0.82 MAPK1 (0.66) RAB9AMAPK1LMNAXBP1FAAH
SCHEMBL3136679 0.80 MAPK1 (1.00) RAB9AMAPK1LMNAXBP1FAAH
SCHEMBL1821157 0.80 MAPT (0.74) RAB9AMAPK1LMNAXBP1FAAH
SCHEMBL3156221 0.80 MAPT (0.74) RAB9AMAPK1LMNAXBP1FAAH
SCHEMBL5221579 0.77 FFAR2 (0.44) RAB9AMAPK1MAPTGAASMN1; SMN2
SCHEMBL1819292 0.77 KMT2A (0.51) RAB9ALMNAGAASMN1; SMN2FFAR2
SCHEMBL1818867 0.76 CCNA2 (0.55) RAB9AMAPTGAASMN1; SMN2FFAR2
SCHEMBL12676939 0.75 MAPK1 (0.60) RAB9AMAPK1LMNAXBP1FAAH
Iodide SCHEMBL1820674 0.74 MAPK1 (0.58) RAB9AMAPK1LMNAXBP1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705050-B2 Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2010-04-27 US claimed
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 EP claimed
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-16 US claimed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 EP claimed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 WO claimed
US-7705050-B2 Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2010-04-27 US disclosed
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 EP disclosed
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-16 US disclosed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 EP disclosed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils CXCL8, MMP8, CCR8 RAB9A 1083/4885MAPK1 2258/4885LMNA 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.